Overview

LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Status:
NOT_YET_RECRUITING

Trial end date:
2028-09-28

Target enrollment:

Participant gender:

Summary

This is a phase III Multicenter, Randomized study evaluating the efficacy and Safety of LM-108(an Anti-CCR8 mAb) in combination With Toripalimab Versus Paclitaxel Injection in subjects with CCR8-Positive locally advanced or metastatic Gastric Cancer and Gastroesophageal Junction Adenocarcinoma.

Phase:

PHASE3

Details

Lead Sponsor:

LaNova Medicines Limited

Treatments:

toripalimab